UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B

Gut, 2011-02, Vol.60 (2), p.247-254

2011

Volltextzugriff (PDF)

Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

Antimicrobial Agents and Chemotherapy, 2004-09, Vol.48 (9), p.3498-3507

2004

Volltextzugriff (PDF)

Adenosine triphosphate bioluminescence to validate decontamination of endoscopes

The Journal of hospital infection, 2017-12, Vol.97 (4), p.353-356

2017

Volltextzugriff (PDF)

826 SAFETY AND EFFICACY OF TWICE DAILY VERSUS EVERY 8 HOUR TELAPREVIR WITH PEGINTERFERON/RIBAVIRIN (PR) IN PATIENTS WITH CIRRHOSIS

Journal of hepatology, 2013-04, Vol.58, p.S338-S339

2013

Volltextzugriff (PDF)

A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B

Journal of hepatology, 2017, Vol.66 (1), p.S688-S689

2017

Volltextzugriff (PDF)

The relationships between IFNL4 genotype, intrahepatic interferon‐stimulated gene expression and interferon treatment response differs in HCV‐1 compared with HCV‐3

Alimentary pharmacology & therapeutics, 2015-08, Vol.42 (3), p.296-306

2015

Volltextzugriff (PDF)

P427 POTENTIAL IMPACT OF IMPROVED TREATMENT ON DISEASE BURDEN OF CHRONIC HEPATITIS C IN AUSTRALIA

Journal of hepatology, 2014-04, Vol.60 (1), p.S210-S210

2014

Volltextzugriff (PDF)

P0195 : Development of a smartphone application to enable remote monitoring in the outpatient management of cirrhotic ascites

Journal of hepatology, 2015-04, Vol.62, p.S378-S378

2015

Volltextzugriff (PDF)

P1093 CXCL-8 PREDICTS HBeAg SEROCONVERSION AND POST TREATMENT FLARES IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH INTERFERON (IFN)-ALFA

Journal of hepatology, 2014-04, Vol.60 (1), p.S442-S442

2014

Volltextzugriff (PDF)

P538 ADHERENCE TO QUALITY OF CARE INDICATORS FOR CIRRHOSIS RELATED ASCITES IS ASSOCIATED WITH IMPROVED PATIENT OUTCOMES

Journal of hepatology, 2014-04, Vol.60 (1), p.S249-S249

2014

Volltextzugriff (PDF)

P0702 : CC IL28B Genotype is associated with high liver necroinflammation and increased expression of TH1 cytokines (CYK) and chemokines (CHK), but also higher TH2 CYK which may drive low ISG expression

Journal of hepatology, 2015-04, Vol.62, p.S586-S586

2015

Volltextzugriff (PDF)

Cyanoacrylate in the treatment of gastric varices complicated by multiple pulmonary emboli

Internal medicine journal, 2006-07, Vol.36 (7), p.462-465

2006

Volltextzugriff (PDF)

O10 SAFETY AND EFFICACY OF THE ALL-ORAL REGIMEN OF MK-5172/MK-8742 ± RIBAVIRIN IN TREATMENT-NAIVE, NON-CIRRHOTIC, PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: THE C-WORTHY STUDY

Journal of hepatology, 2014-04, Vol.60 (1), p.S5-S5

2014

Volltextzugriff (PDF)

466 INTERLEUKIN-28B rs12979860 C ALLELE IS PROTECTIVE AGAINST ADVANCED FIBROSIS IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT

Journal of hepatology, 2013-04, Vol.58, p.S191-S191

2013

Volltextzugriff (PDF)

P1209 FACTORS INFLUENCING RENAL FUNCTION IN PATIENTS RECEIVING TELAPREVIR TWICE DAILY OR EVERY 8 HOURS: RESULTS FROM THE PHASE III OPTIMIZE STUDY

Journal of hepatology, 2014-04, Vol.60 (1), p.S491-S491

2014

Volltextzugriff (PDF)

P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDY

Journal of hepatology, 2014-04, Vol.60 (1), p.S527-S528

2014

Volltextzugriff (PDF)

625 TOLL LIKE RECEPTOR AGONIST INDUCED IFN-γ RESPONSES BY NATURAL KILLER CELLS IN CHRONIC HEPATITIS B INFECTION

Journal of hepatology, 2010, Vol.52, p.S245-S245

2010

Volltextzugriff (PDF)

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

The Lancet (British edition), 2015-03, Vol.385 (9973), p.1075-1086

2015

Volltextzugriff (PDF)

901 VITAMIN D STATUS AND LIVER HISTOLOGY IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT

Journal of hepatology, 2012-04, Vol.56, p.S350-S351

2012

Volltextzugriff (PDF)

1126 VITAMIN D STATUS IS ASSOCIATED WITH COMPLETE EVR BUT NOT SVR IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT

Journal of hepatology, 2012-04, Vol.56, p.S443-S444

2012

Volltextzugriff (PDF)

798 EFFICACY OF TELAPREVIR DOSED TWICE DAILY VERSUS EVERY 8 HOURS BY IL28B GENOTYPE: RESULTS FROM THE PHASE III OPTIMIZE STUDY

Journal of hepatology, 2013-04, Vol.58, p.S326-S326

2013

Volltextzugriff (PDF)

462 THE ASSOCIATION BETWEEN HAEMOGLOBIN DECLINE AND SVR IS INDEPENDENT OF ITPA GENOTYPE DURING PEG-INTERFERON PLUS RIBAVIRIN THERAPY FOR HCV-1: ANALYSIS FROM THE CHARIOT STUDY

Journal of hepatology, 2013-04, Vol.58, p.S189-S190

2013

Volltextzugriff (PDF)

905 ADHERENCE WITH TELAPREVIR BID vs. q8h DOSING IN TREATMENT-NAÏVE HCV-INFECTED PATIENTS: RESULTS FROM THE PHASE III OPTIMIZE STUDY

Journal of hepatology, 2013-04, Vol.58, p.S373-S373

2013

Volltextzugriff (PDF)

O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS

Journal of hepatology, 2014-04, Vol.60 (1), p.S524-S525

2014

Volltextzugriff (PDF)

919 ANEMIA AND ITS MANAGEMENT IN PATIENTS TREATED WITH TELAPREVIR TWICE DAILY VERSUS EVERY 8 HOURS IN THE PHASE III OPTIMIZE STUDY

Journal of hepatology, 2013-04, Vol.58, p.S379-S379

2013

Volltextzugriff (PDF)

1 – 25 von 659

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(524)
Mit Volltextzugriff
(516)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(512)
Deutsch
(145)
Spanisch
(1)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B

Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

Adenosine triphosphate bioluminescence to validate decontamination of endoscopes

826 SAFETY AND EFFICACY OF TWICE DAILY VERSUS EVERY 8 HOUR TELAPREVIR WITH PEGINTERFERON/RIBAVIRIN (PR) IN PATIENTS WITH CIRRHOSIS

A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B

The relationships between IFNL4 genotype, intrahepatic interferon‐stimulated gene expression and interferon treatment response differs in HCV‐1 compared with HCV‐3

P427 POTENTIAL IMPACT OF IMPROVED TREATMENT ON DISEASE BURDEN OF CHRONIC HEPATITIS C IN AUSTRALIA

P0195 : Development of a smartphone application to enable remote monitoring in the outpatient management of cirrhotic ascites

P1093 CXCL-8 PREDICTS HBeAg SEROCONVERSION AND POST TREATMENT FLARES IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH INTERFERON (IFN)-ALFA

P538 ADHERENCE TO QUALITY OF CARE INDICATORS FOR CIRRHOSIS RELATED ASCITES IS ASSOCIATED WITH IMPROVED PATIENT OUTCOMES

P0702 : CC IL28B Genotype is associated with high liver necroinflammation and increased expression of TH1 cytokines (CYK) and chemokines (CHK), but also higher TH2 CYK which may drive low ISG expression

Cyanoacrylate in the treatment of gastric varices complicated by multiple pulmonary emboli

O10 SAFETY AND EFFICACY OF THE ALL-ORAL REGIMEN OF MK-5172/MK-8742 ± RIBAVIRIN IN TREATMENT-NAIVE, NON-CIRRHOTIC, PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: THE C-WORTHY STUDY

466 INTERLEUKIN-28B rs12979860 C ALLELE IS PROTECTIVE AGAINST ADVANCED FIBROSIS IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT

P1209 FACTORS INFLUENCING RENAL FUNCTION IN PATIENTS RECEIVING TELAPREVIR TWICE DAILY OR EVERY 8 HOURS: RESULTS FROM THE PHASE III OPTIMIZE STUDY

P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDY

625 TOLL LIKE RECEPTOR AGONIST INDUCED IFN-γ RESPONSES BY NATURAL KILLER CELLS IN CHRONIC HEPATITIS B INFECTION

901 VITAMIN D STATUS AND LIVER HISTOLOGY IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT

1126 VITAMIN D STATUS IS ASSOCIATED WITH COMPLETE EVR BUT NOT SVR IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT

798 EFFICACY OF TELAPREVIR DOSED TWICE DAILY VERSUS EVERY 8 HOURS BY IL28B GENOTYPE: RESULTS FROM THE PHASE III OPTIMIZE STUDY

462 THE ASSOCIATION BETWEEN HAEMOGLOBIN DECLINE AND SVR IS INDEPENDENT OF ITPA GENOTYPE DURING PEG-INTERFERON PLUS RIBAVIRIN THERAPY FOR HCV-1: ANALYSIS FROM THE CHARIOT STUDY

905 ADHERENCE WITH TELAPREVIR BID vs. q8h DOSING IN TREATMENT-NAÏVE HCV-INFECTED PATIENTS: RESULTS FROM THE PHASE III OPTIMIZE STUDY

O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS

919 ANEMIA AND ITS MANAGEMENT IN PATIENTS TREATED WITH TELAPREVIR TWICE DAILY VERSUS EVERY 8 HOURS IN THE PHASE III OPTIMIZE STUDY

Suchergebnisse filtern